| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
Form 4: Paravasthu Mukund, Chief Operating Officer
Sold 3,079 shares ($39.6K) |
| 12 Nov 2026 |
Form 4: Brackmann Christoph, Chief Financial Officer
Sold 7,343 shares ($94.4K) |
| 09 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | 144 |
| 09 Nov 2026 |
8-K: Regulation FD Disclosure
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer |
| 04 Nov 2026 |
Form 4: Puri Michal Nath, Chief Human Resources Officer
Sold 660 shares ($8.74K) |
| 29 Oct 2026 | S-8 |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
Third quarter net revenues of $193 million an increase of 16% year-over-year, driven by 19% growth in active patients worldwide |
| 29 Oct 2026 | 10-Q |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure
Baar, Switzerland – October 1, 2026 – Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advance... |
| 09 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
(b) Timothy Scannell, a current director of NovoCure Limited (the “Company”), has retired from the Board and his seat was formally vacated pursuant to the Company’s Articles of Association effective September 2, 2026. Mr. Scannell's reti... |
| 01 Sep 2026 |
8-K: Other Events
In mid-August 2026, NovoCure Limited (the "Company," "we," or "us") through a subsidiary, became aware of unauthorized access to some of its information systems. Upon detecting the unauthorized access, the Company activated its cybersecu... |
| 23 Jul 2026 | 144 |
| 23 Jul 2026 |
8-K: Results of Operations and Financial Condition
Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications |
| 23 Jul 2026 | 10-Q |
| 01 Jul 2026 |
Form 4: Puri Michal Nath, Chief Human Resources Officer
Received 1,905 shares as a grant or award ($21.2K) |
| 01 Jul 2026 |
Form 4: Leonard Frank X, Chief Executive Officer
Received 1,905 shares as a grant or award ($21.2K) |
| 01 Jul 2026 |
Form 4: Ben Arye Barak, General Counsel
Received 1,299 shares as a grant or award ($14.5K) |
| 01 Jul 2026 |
Form 4: Danziger Asaf, Director
Received 268 shares as a grant or award ($2.99K) |
| 30 Jun 2026 |
8-K: Regulation FD Disclosure
The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with gemcitabine and nab-paclitaxel |
Loading...